GLP-1 Exposure Around Conception Shows No Clear Increase in Pregnancy Risks
Women exposed to glucagon-like peptide-1 (GLP-1) receptor agonists around the time of conception do not experience a clearly detectable increase in adverse outcomes for themselves or their babies, according to a systematic review and meta-analysis published in the journal Med on September 29, 2026. Researchers analyzed data from 2,118,215 pregnancies across ten studies to evaluate risks linked to early exposure before or just after conception.
Among the total pregnancies reviewed, 8,325 involved women exposed to a GLP-1 receptor agonist around conception and within six months before a positive pregnancy test. Compared with unexposed pregnancies, investigators observed no clear increase in the risk of miscarriage, stillbirth, congenital anomalies, preterm birth, gestational diabetes, high blood pressure, or excessive maternal weight gain. Because many pregnancies are unplanned, study authors noted that accidental exposure to these medications remains likely as use grows among women of reproductive age.
Data From Two Million Pregnancies Informs New Study
Lead author Asma Khalil, professor of obstetrics and maternal foetal medicine at City St George’s, University of London, stated that patients should not panic if they discover they were taking a GLP-1 medication before realizing they were pregnant. Khalil advised speaking to a healthcare team for personalized guidance and support.
However, the study authors emphasized that their findings do not prove the medications are safe to use throughout pregnancy, pointing to the need for further research.
Regulatory Guidance Recommends Stopping Treatment Before Pregnancy
Current official standards diverge from the observational findings. Guidance published by the Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026 states that GLP-1 medicines should not be taken during pregnancy or immediately prior to trying to conceive due to insufficient safety data regarding potential harm to the fetus. The MHRA advises stopping semaglutide at least two months, and tirzepatide at least one month, before attempting pregnancy, based on animal studies that indicated fetal harm.
Ashifa Trivedi, clinical lead pharmacist in medicines and neonates at Evelina London Children’s Hospital, told The Pharmaceutical Journal that the Med findings are reassuring given how common inadvertent early exposure is becoming. However, Trivedi stressed that finding no detectable increase in adverse outcomes in observational data is not the same as demonstrating safety for active use during pregnancy.
Trivedi noted that significant gaps remain regarding the effects of individual GLP-1 drugs and exposure timing during different stages of gestation. She confirmed that the new meta-analysis does not alter current clinical recommendations advising against GLP-1 use during pregnancy and requiring discontinuation ahead of planned conceptions.
Frequently Asked Questions About GLP-1 Pregnancy Risks
What should a patient do if they take a GLP-1 medication and discover they are pregnant?
Patients who discover they were taking a GLP-1 receptor agonist before realizing they were pregnant should contact their healthcare team immediately for personalized advice and support, according to City St George’s professor Asma Khalil.
How far in advance must specific GLP-1 medications be stopped before trying to conceive?
According to February 2026 guidance from the Medicines and Healthcare products Regulatory Agency, patients should stop semaglutide at least two months and tirzepatide at least one month before attempting to become pregnant.
Why are GLP-1 medications restricted during pregnancy despite the new study?
The Medicines and Healthcare products Regulatory Agency maintains that existing safety data is insufficient to rule out harm to the baby, noting that animal studies found GLP-1 receptor agonists were harmful to the unborn fetus.